Yu Yang

Yu Yang

Auto-generated profile, based on publicly available information

Yu Yang

College of Enology, Northwest A&F University, 22 Xinong Road, 712100 Yangling, Shaanxi, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
YYYu Yang
Yu Yang
SFStephanie Frank
Stephanie Frank
XWXibu Wei
Xibu Wei
XWXingjie Wang
Xingjie Wang
YLYunkui Li
Yunkui Li
YTYongsheng Tao
Yongsheng Tao

18 February 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
LLLimin Liao
Limin Liao
QLQinggang Liu
Qinggang Liu
HCHuiling Cong
Huiling Cong
ZXZhihui Xu
Zhihui Xu
ELEnhui Li
Enhui Li
JDJinkai Dong
Jinkai Dong
Objective: To evaluate the efficacy and safety of Hengli® Chinese botulinum toxin type A (BTX-A; 100 U) in Chinese patients with overactive bladder.Methods: This study was a multicenter, randomized, double-blind, placebo-controlled trial in Chinese patients who were inadequately managed with anticholinergic medications. Eligible patients were randomized 2:1 to receive intradetrusor injections of Hengli® BTX-A (n = 144) or placebo (n = 72). The primary endpoint was the change in the number of daily micturition episodes at week 6 from baseline. The secondary efficacy endpoints included the average frequency of urgency and urinary incontinence (UI) episodes per day, urgency score, average micturition volume per day, OABSS, and QoL score.Results: In the Hengli® BTX-A group, there was a significantly greater reduction in the average number of micturition episodes per 24 h compared with the placebo group (3.28 vs. 1.43; p = 0.003). Moreover, there was a significantly greater improvement in the daily number of urgency episodes, micturition volume and OABSS score. An increased post-void residual urine volume, dysuria, and urinary tract infection represented adverse events (AEs) in the Hengli® BTX-A group. Most AEs were mild or moderate in severity. One patient in the BTX-A group initiated clean intermittent catheterization (CIC) during treatment.Conclusion: Hengli® BTX-A treatment was well-tolerated and resulted in significant improvements in OAB symptoms among Chinese patients inadequately managed by anticholinergics.Clinical Trial Registration:http://www.chinadrugtrials.org.cn/clinicaltrials.prosearch.dhtml, Identifier: CTR20131190.

24 July 2020 in European Food Research and Technology
Verified
Journal Article
Closed access
PDF file
XWXing-Jie Wang
Xing-Jie Wang
HSHong-Cong Song
Hong-Cong Song
YYYu Yang
Yu Yang
YTYongsheng Tao
Yongsheng Tao